Physician profile
Michael Duffy
NPI 1689635328
$7,209.08
in general payments reported to CMS, 2019-2025
47 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $34.22 · 2021: $894 · 2022: $968 · 2023: $1,726 · 2024: $1,100 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,316.51 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $1,053.73 | 2021-2025 | Ubrelvy, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals Lp | $603.72 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $571.10 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $522.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.38 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $312.78 | 2022-2025 | Verquvo, Gardasil 9, Capvaxive |
| Novo Nordisk INC | $309.38 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $214.15 | 2022-2024 | Freestyle Libre 3, Eterna |
| Sanofi-Aventis U.S. LLC | $151.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $129.56 | 2023-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $126.98 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Vifor Pharma, INC. | $121.82 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $120.84 | 2024 | Inpefa |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.